U.S. judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims
A U.S. judge has rejected Bayer’s request for an injunction to block Johnson & Johnson’s alleged false advertising that its multibillion-dollar drug cuts the risk of death from prostate cancer in half.














